Free Trial
NASDAQ:NERV

Minerva Neurosciences Q4 2024 Earnings Report

Minerva Neurosciences logo
$1.76 0.00 (0.00%)
Closing price 04/28/2025 03:50 PM Eastern
Extended Trading
$1.63 -0.13 (-7.39%)
As of 04:05 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Minerva Neurosciences EPS Results

Actual EPS
-$0.56
Consensus EPS
-$1.05
Beat/Miss
Beat by +$0.49
One Year Ago EPS
N/A

Minerva Neurosciences Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Minerva Neurosciences Announcement Details

Quarter
Q4 2024
Time
Before Market Opens
Conference Call Date
Monday, February 24, 2025
Conference Call Time
6:00PM ET

Upcoming Earnings

Minerva Neurosciences' Q1 2025 earnings is scheduled for Tuesday, April 29, 2025

Minerva Neurosciences Earnings Headlines

Minerva Neurosciences (NASDAQ:NERV) Now Covered by StockNews.com
Minerva Neurosciences Inc.
Trump’s treachery
Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to move your money now.
Minerva Neurosciences regains Nasdaq compliance
See More Minerva Neurosciences Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Minerva Neurosciences? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Minerva Neurosciences and other key companies, straight to your email.

About Minerva Neurosciences

Minerva Neurosciences (NASDAQ:NERV), a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone (MIN-101) for the treatment of negative symptoms in patients with schizophrenia, currently submitted an New Drug Application (NDA); and MIN-301, a soluble recombinant form of the neuregulin-1b1 protein for the treatment of Parkinson's disease and other neurodegenerative disorders. The company has a license agreement with Mitsubishi Tanabe Pharma Corporation to develop, sell, and import roluperidone globally excluding Asia. Minerva Neurosciences, Inc. was incorporated in 2007 and is based in Burlington, Massachusetts.

View Minerva Neurosciences Profile

More Earnings Resources from MarketBeat